Key result
NO-releasing GSNO increased cGMP in 18% of viable cardiac myocytes co-cultured with cardiac fibroblasts (p<0.05), an effect abolished by gap junction inhibitors and absent in isolated myocytes.
Why the study?
Despite numerous reports regarding NO-induced cGMP effects in the heart, the underlying cGMP signals remain poorly characterized.
Does nitric oxide-induced cGMP generated in cardiac fibroblasts transfer into cardiac myocytes via gap junctions?
Does nitric oxide-induced cGMP generated in cardiac fibroblasts transfer into cardiac myocytes via gap junctions?
This preclinical study demonstrates that NO-induced cGMP in the heart is synthesized in cardiac fibroblasts rather than myocytes and enters cardiomyocytes via gap junctions, providing a novel intercellular mechanism for how guanylyl cyclase stimulators and activators affect cardiomyocytes.
Answers are grounded in this paper and cite their sources.
Does not support direct NO effects on myocytes; leaves open gap junction transfer in human hearts.
BACKGROUND AND PURPOSE: The intracellular signalling molecule cGMP, formed by NO-sensitive GC (NO-GC), has an established function in the vascular system. Despite numerous reports about NO-induced cGMP effects in the heart, the underlying cGMP signals are poorly characterized. EXPERIMENTAL APPROACH: Therefore, we analysed cGMP signals in cardiac myocytes and fibroblasts isolated from knock-in mice expressing a FRET-based cGMP indicator. KEY RESULTS: Whereas in cardiac myocytes, none of the known NO-GC-activating substances (NO, GC activators, and GC stimulators) increased cGMP even in the presence of PDE inhibitors, they induced substantial cGMP increases in cardiac fibroblasts. As cardiac myocytes and fibroblasts are electrically connected via gap junctions, we asked whether cGMP can take the same route. Indeed, in cardiomyocytes co-cultured on cardiac fibroblasts, NO-induced cGMP signals were detectable, and two groups of unrelated gap junction inhibitors abolished these signals. CONCLUSION AND IMPLICATION: We conclude that NO-induced cGMP formed in cardiac fibroblasts enters cardiac myocytes via gap junctions thereby turning cGMP into an intercellular signalling molecule. The findings shed new light on NO/cGMP signalling in the heart and will potentially broaden therapeutic opportunities for cardiac disease.
No takes yet. Share an insight, caveat, or question.
Menges et al. (2019) studied Cardiac NO/cGMP intercellular signalling. NO-GC-activating substances (GSNO, BAY41-2272, BAY41-8543, BAY60-2770) and gap junction inhibitors (carbenoxolone, 18α/β-glycyrrhetinic acid, GAP26, GAP27) vs. Control conditions, non-touching co-cultures, or scrambled peptides (sGAP26, sGAP27) was evaluated on Intracellular cGMP signals (% change of emission ratio [% CER] via FRET imaging) and fraction of GSNO-responsive cardiac myocytes in fibroblast-myocyte co-cultures (p=<0.05). NO-releasing GSNO increased cGMP in 18% of viable cardiac myocytes co-cultured with cardiac fibroblasts (p<0.05), an effect abolished by gap junction inhibitors and absent in isolated myocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: